Manitoba Life Science News for the week ending June 4, 2010

Jun 7, 2010 | Corporate Member News

LSAM_RGB_large (260 x 260)

Summary of this Week’s Newsletter:

LSAM Presents A Workshop on SR&ED Tax Credits- June 8, 2010

  • The CRA offers more than $4 billion annually in SR&ED funding, yet fewer than 50% of eligible Canadian companies apply. And those who do apply may receive minimal refunds because they fail to take full advantage of the program. Join us for a program designed to get you your maximum return.

Upcoming Events

  • Nominations and Applications Are Now Open for the 2010 Manitoba Business Awards
  • The University of Manitoba’s Technology Transfer Office Presents, Ribs on the Red- June 23, 2010
  • National Biotechnology Week 2010 – September 17-24, 2010
  • Future LSAM Events

LSAM Training Events

  • LSAM’s June Training Calendar- An Overview

Member & Local News

  • The Alliance of Manitoba Sector Councils Add New Staff
  • City’s CIC to Manage Consortium
  • Merck Launches Global Trial Network for Cancer-Drug Creation

Life Science in the News

  • Canada Finds $1M Savings in Vax Distribution Plan Clean-Up
  • WHO Says H1N1 Remains Pandemic
  • MS Patients to Launch Rights Complaints Demanding Unproven Treatment
  • Open Source Systems Lure Drug Developers
  • Bio-glue Holds Promise as a Wound-Healing Agent
  • Finding a Cure for Counterfeit Drugs: Technologies that Combat Vulnerabilities in the Pharmaceutical Supply Chain
  • Q+A – What Happens if EU Relaxes GMO Rules?
  • Entrepreneurs Flock to Cleantech Sector
  • ORNL Researchers Develop Acetate-Tolerant Microorganism for Wood-to-Biofuels

Don’t Miss Out On the Opportunity To Recoup Valuable Dollars For Your Company- June 8, 2010

If your organization invests time and money in research, experimental development or technical work, you could be eligible for significant tax credits through the Canada Revenue Agency’s Scientific Research and Experimental Development (SR&ED) Tax Incentive Program.

The SR&ED program uses federal tax credits and refunds to support business of all sizes in all sectors who engage in research and development. This means that no matter what industry you’re in, you can turn R&D investments into either cash refunds or tax credits.

Unfortunately, though the CRA offers more than $4 billion annually in SR&ED funding, fewer than 50% of eligible Canadian companies apply. And those who do apply may receive minimal refunds because they fail to take full advantage of the program.

That’s where LSAM can help…

SR&ED Tax Credit presentation- June 8, 2010

What is the SR&ED Program?

The scientific Research and Experimental Development (SR&ED) program is a federal tax incentive program to encourage Canadian businesses of all sizes and in all sectors to conduct research and development (R&D) in Canada that will lead to new, improved, or technologically advanced products or processes. The SR&ED program is the largest single source of federal government support for industrial research and development.

Claimants can apply for SR&ED investment tax credits for expenditures such as wages, materials, machinery, equipment some overhead, and SR&ED contracts.

Join Hartley Miller and Donald Sobkow of The Recoup Group, Inc for a 90 minute presentation designed to provide you with the valuable knowledge on the SR&ED Tax Credit Program. This presentation will provided you with practical information about understand the program and much more.

When:              Tuesday, June 8, 2010

Where:            1000 Waverley Street

Time:               8:30-10:30am

Cost:                FREE for LSAM Members ($10 for non-members)

What You’ll Get:

  • SR&ED Program Overview
  • Tax Credit Rates (Federal and Provincial)
  • Reporting Deadlines
  • Program Criteria
  • How to Identify Eligible projects
  • Specific Life Science Examples
  • What Expenditures Qualify/Don’t Qualify
  • Program Myths
  • Role of the Tax Payer (maintain contemporaneous documentation)
  • How to file (T661 input)
  • The Review Process
  • The ‘Recoup Process”
  • Question & Answer Session

The Recoup Group, Inc, is a Manitoba based Canadian firm dedicated to the identification and recovery of Scientific Research & Experimental Development (SR&ED) Refunds. The Recoup Group, Inc. team has a wealth of knowledge and a significant track record ( 20 years) in identifying projects, claiming all related expenditures and negotiating SR&ED refunds. Our corporate philosophy is to work with our client’s as part of their internal team to recognize SR&ED projects and activities, accumulate and prepare technical and costing documentation and to make sure they have set up their internal infrastructure to take full advantage of the SR&ED program in an efficient manner.

This is an opportunity that should not be missed. To register visit Alternatively you can contact LSAM’s Training Coordinator, Norma Niefer at (204) 272-5095 or [email protected].


Nominations and Applications Are Now Open for the 2010 Manitoba Business Awards

The Manitoba Chambers of Commerce is proud to announce the 2010 Manitoba Business Awards.

The open categories are: Outstanding Small Business, Outstanding Medium Business, Outstanding Large Business, Long Term Business – Winnipeg, Long Term Business – Rural Manitoba, and the Lieutenant Governor’s Award: Outstanding Contribution to the Community by a Business. Could this be your year?

The Awards will be presented on November 3, 2010 at the Business Excellence Gala Dinner, which will be held at the Winnipeg Convention Centre. 

The deadline for applications and nominations is July 7, 2010:

The University of Manitoba’s Technology Transfer Office Presents, Ribs on the Red- June 23, 2010

You are invited to join the Technology Transfer Office at the University of Manitoba for their annual Ribs on the Red event on June 23rd at the University of Manitoba.

This year’s “Rib’s” event will feature Christopher Gram of Mueting, Raasch & Gebhardt brings his experience as IP attorney covering medical devices, pharmaceuticals, and biotech. Before joining MRG, Christopher was in-house Intellectual Property Counsel for 3M Company’s Pharmaceuticals Division.

This is always a great event and one that should not be missed. Space is limited so RSVP today!

National Biotechnology Week 2010 (Powered by the Bio-economy) 

National Biotechnology Week is a Canada-wide event celebrating the accomplishments and contribution that life sciences makes to the economy and to the lives of Canadians.

Last year’s events brought over 3000 Canadians together to explore the bio-based economy. Sold-out events across Canada explored the future of biotechnology — from new financing models, to the road to commercialization and how to grow tomatoes on mars.

The theme of this year’s National Biotechnology Week is “powered by the bio-economy.” As the bio-economy grows, understanding the convergence of biotechnology with traditional industries, processes and ways of doing business is key. This year, the week will focus on increasing corporate visibility through site and facility tours; and increasing awareness among media and public of what is a bio-economy.

Join LSAM and BIOTECanada as we once again celebrate Canadian scientific and business excellence in bringing the best of biotech to the public. Visit our National Biotechnology Week website to learn how to get involved.


  • Ernst & Young Report on Biotechnology- Mid July
  • 11th Annual LSAM Golf Tournament- August 9th, 2010
  • National Biotechnology Week Launch- September 16, 2010
  • National Biotechnology Week- September 17-24, 2010
  • LSAM Annual Dinner- October 5, 2010


June event calendar

Below is a listing of LSAM Training Programs being offered for the month of June.

 June 8, 2010 –                         A Quality Systems Approach to Risk-Based Technology Transfer-Reducing Regulatory Problems and Improving Performance

June 8, 2010 –                         SR&ED Tax Credit Program

June 8 and 9, 2010 –               QNET-Project Management: A Practical Approach

June 9, 2010-                          Using Microbiological Rapid Methods for Faster Release of Oral and other Non-Sterile Products from Pharmaceuticals to Food Products

June 10, 2010-                        Decreasing Environmental, Raw Material and In-Process Testing Requirements in a cGMP Environment- Without Diminishing Quality

June 15, 2010 –                       QNET-Peel the Skin: Tools for Innovative Discovery

June 16, 2010-                        QNET- The Essence of Good Governance

June 16, 2010 –                       Air Flow Visualization Studies in Support of Aseptic Manufacturing

June 21, 2010 –                       2010 Changes to the EU Variation Rules

June 21, 2010-                        Drug Master Files, Understanding & Meeting Your Global Regulatory & Processing Responsibilities

June 24, 2010 –                       Selling your Product or Service to the Province of Manitoba

June 24, 2010 –                       Selling your Product or Service to the Government of Canada

June 24, 2010 –                       Selling your Product or Service to the City of Winnipeg

June 25, 2010 –                       The Challenges of Monitoring Impurities in Pharmaceutical Products

June 29, 2010 –                       Write it Right!

If further information on any of the courses is required or to register, please visit:


The Alliance of Manitoba Sector Councils Add New Staff

The Alliance of Manitoba Sector Councils is pleased to welcome Barry Miller and Joe Di Curzio to their team! 

Taking on the challenging role of Case Managers of the Workforce Integration of Skilled Newcomers in the Trades (WISNIT) project, Barry and Joe will formally join the Alliance team on July 19th. 

WISNIT is a 3 year project funded by HRSDC in partnership with the Province of Manitoba that will assist newcomers with the preparation for their Certification Examination through Trades

Qualifications (TQ) and meet Manitoba’s skilled-trades labour demands.

City’s CIC to Manage Consortium

Winnipeg’s Composites Innovation Centre was introduced as the manager of a newly created national composites R&D consortium at an event in Ottawa Tuesday.

The Canadian Composites Manufacturing Research and Development consortium (CCMRD) was formed in co-operation with the Composites Innovation Centre (CIC), the National Research Council Canada’s Institute for Aerospace Research (NRC-IAR) in Ottawa, and the Boeing Company.

Merck Launches Global Trial Network For Cancer-Drug Creation

Merck & Co. Inc. announced the launch of a global clinical trial network focusing on the development of cancer drugs and vaccines.

The effort is intended to speed up the development of cancer drugs through simplified procedure and better funding efforts, the pharmaceutical giant said. It also noted a recent Institute of Medicine report that about half of all cancer studies are never completed due to various reasons such as cumbersome procedures, bureaucracy and poor coordination.


Canada Finds $1M Savings in Vax Distribution Plan Clean-Up

From chaos emerges efficiency–thanks to the lean process. In late 2008, the Saskatchewan Ministry of Health’s Population Health Branch began a project to improve vaccine storage, shipping and receiving practices at the provincial shipping depot, as over-processing had gummed up the vaccine-shipment works. 

In order to fulfill orders arriving by fax from Saskatoon, Regina depot employees used to pack coolers with vaccine for shipment via internal mail. Saskatoon, for its part, hired a temp worker to unpack the boxes and then repackage the contents for shipments to rural and urban health centers. 

In a lean upgrade to this onerous process, the storage depot now ships vaccine directly to healthcare facilities outside of Saskatoon, eliminating the cold chain unpacking and repackaging steps.  The Regina staff then selected a refrigeration courier service. The courier picks up the shipment at the depot, takes it to a refrigeration unit in Saskatoon, and makes the deliveries the next morning.

WHO Says H1N1 Remains Pandemic

WHO Director-General Margaret Chan on Thursday announced the WHO still considers H1N1 (swine) flu a pandemic, despite the fact “its most intense activity has passed in many parts of the world,” Reuters reports (Lynn, 6/3).

Chan released a statement regarding the WHO’s decision, which came “two days after a virtual meeting of international flu experts who advise her on setting the global body’s pandemic alert level,” the Associated Press reports (6/3).

“Chan’s decision, based on the committee’s recommendation, means that the outbreak, widely known as swine flu, remains at phase 6 on the WHO’s pandemic scale,” where it has been since June 2009, Reuters continues, adding that the WHO’s “guidance on whether a disease constitutes a pandemic determines how its 193 member governments handle an outbreak, including stockpiling vaccines and antivirals” (6/3).

MS Patients to Launch Rights Complaints Demanding Unproven Treatment

Multiple sclerosis patients in at least two provinces are preparing to launch human rights complaints as they demand access to an unproven treatment that has excited the hopes of people living with the degenerative disease and already prompted some to seek the procedure abroad.

A group of patients in British Columbia and another man with the disease in Newfoundland say denying them treatment for a vein condition that’s been called chronic cerebrospinal venous insufficiency, or CCSVI, amounts to discrimination.

An Italian doctor recently claimed narrowed neck veins cause or contribute to MS and unblocking them could help treat the disease, but the procedure isn’t offered in Canada as the medical community waits for large-scale clinical trials and studies to test the theory.

Open Source Systems Lure Drug Developers

The gradual spread of software automation in drug development may be getting a boost from open source systems. Most e-clinical systems today–from data capture and storage to trial management and operations–are proprietary, despite the excellent work that solutions providers have done to make their products compatible with existing standards-based and de facto standard industry systems.

True to the open source concept, such systems tend to be more accessible to the resource-constrained academic and small biotech sectors, as well as small and mid-size CROs. Open systems are available for free, with no license fee, and they provide an opportunity for interaction with other community members via the shared solution building, refining, and follow-on development that underlies them, says Ben Bauman, director for business development at Akaza Research, in an interview. The company’s OpenClinica system is an open-source EDC and data management system.

Bio-glue Holds Promise as a Wound-Healing Agent

A sticky gel made from a compound found in a tanning spray promises to work as a new wound healing agent, according to a group of biomedical engineers at Cornell.

The gel helped to heal the wounds made during surgery, say plastic surgeons at NewYork-Presbyterian Hospital/Weill Cornell Medical Center in New York City. And it might prove effective in filling the tissue gaps left by breast cancer surgery.

The team tested the efficacy of MPEG-pDHA, which includes the sticky compound that allows tanning solution to adhere to the skin. Unlike other types of bio-glues, it’s easily removed from the body. DHA was bound to a “protecting group molecule” that made it manageable. That mixture was used to make a polymer that could be injected with a needle.

Finding a Cure for Counterfeit Drugs: Technologies that Combat Vulnerabilities in the Pharmaceutical Supply Chain

Drug counterfeiting continues to increase and likewise, its global threat to patient safety continues to rise. The World Health Organization (WHO) estimates that one million deaths occur from counterfeit malaria drugs every year.  And while the United States drug supply is one of the safest in the world, it is not immune to these concerns.  It is important for pharmaceutical manufacturers to understand not just the different types of threats they face but also the tools and technologies available today to prevent counterfeit drugs from entering the supply chain.

Once a drug leaves its manufacturer it is left wide open to be adulterated, completely faked, diluted, relabeled, and repackaged or manufactured without authorization.  While the counterfeit is often physically indistinguishable from the genuine product, most of the time the counterfeit does not provide the intended therapeutic value. 

In order for a manufacturer to the reach complete product security, it’s important to understand the different types of drug supply chain security threats. Those five major threats are: theft, illegal transport from one country to another, counterfeiting, contract breach, and fraud. 

Q+A – What Happens if EU Relaxes GMO Rules?

The EU executive European Commission has drawn up plans for a radical overhaul of the 27-nation bloc’s rules on genetically modified (GM) crop cultivation, according to sources, which if approved could see huge growth in plantings in Europe.

Entrepreneurs Flock to Cleantech Sector

Whether it’s wind power, waster recycling, water turbines, solar or carbon capture and storage, entrepreneurs are pouring into the renewable-energies sector.

“It’s no longer the granola crunchers,” said Bill Eggertson executive director of Ottawabased Canadian Association for Renewable Energies. “This is the investor market. Others are coming in wanting to develop new products.”

Alain Jegen would agree. He helps assess pre-commercialization ideas for Sustainable Development Technology Canada (SDTC). The Ottawabased not-for-profit foundation was founded in 2001 by the federal government to provide funding and support to businesses developing clean technologies that address the issues of climate change, clean air, water and soil quality.

ORNL Researchers Develop Acetate-Tolerant Microorganism for Wood-to-Biofuels

Scientists from the U.S. DOE’s Oak Ridge National Laboratory say they have developed a microorganism with an improved ability to convert wood products to biofuel. The researchers identified a key Zymomonas mobilis gene that, when over expressed, allows the microorganism to resist inhibitors.

Currently, biomass materials such as corn stover and switchgrass must undergo pretreatments to loosen the cellular structure enough to extract the sugar from the cellulose. Those treatments add new challenges because they create chemicals called inhibitors that stop microorganisms from performing fermentation. There are two ways to combat that problem, according to Steven Brown, researcher in ORNL’s Bioenergy Research Center. “One way is to remove the inhibitors, but this method is very expensive and would not help biofuels become cost-competitive with gasoline,” he said. “The second way is what we do, which is to develop microorganisms that are more tolerant of the inhibitors.”


Jonathan Frate
Manager, Membership Services
Life Science Association of Manitoba
1000 Waverley Street
Winnipeg, MB     R3T 0P3
Tel: (204) 272-5094
Fax: (204) 272-2961
Email: [email protected]

Similar Posts


advertisement advertisement


Glad to hear that @mbchambersofcom representative on @CdnChamberofCom Board of Directors Paul Provost from @6pmarketing was able to participate in discussion with Deputy PM and Finance Minister @cafreeland in Ottawa #VoiceofBusiness #PoweroftheNetwork